Obesity is a medical condition, sometimes considered a disease, in which excess body fat has accumulated to such an extent that it can potentially have negative effects on health. People are classified as obese when their body mass index (BMI)—a person's weight divided by the square of the person's height—is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight.
Obesity is a major cause of disability and is correlated with various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis.
Obesity is associated with the impairment of normal GH (growth hormone), GLP-1 secretion, and responses to all stimuli such as GH-releasing hormone (GHRH), hypoglycaemia, L-dopa, arginine, glucagon, physical exercise, and sleep.
Glucagon-like peptide-1 (GLP-1) is an endogenous gut hormone and a key regulator in maintaining glucose homeostasis by stimulating insulin secretion.
NA-931: the first Quadruple Action of four major hormones receptors/agonists of IGF-1, GLP-1, GIP and Glucagon
NA-931 has been developed for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
Press release Biomed presented its quadruple agonist NA-931 at the World Obesity Congress, October 24-26, 2024 in Baltimore, Maryland, USA
How does it work?
NA-931™, a quadruple receptor agonist, has demonstrated a proof of efficacy and safety for potential treatment of obesity. NA-931 regulates the homeostasis of IGF-1, GLP-1, GIP and Glucagon to facilitate weight loss without many of the adverse events associated with current obesity drugs.
NA-931 can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:
* NA-931 regulates IGF-1, GLP-1 and GIP and Glucagon
* It has great bioavailability in the body
* It is safe and well tolerated, with no serious adverse events observed
* It has been shown to significantly reduce the body mass index, without muscle loss
* It is available in oral formulation: convenient for patient to take one capsule once a day.
NA-931 is in Phase 2B clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments.
The Phase 3 clinical trials of NA-931 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
Biomed’s team recently presented a keynote lecture on “A Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Attenuates Alcohol-Mediated Behavior,” showcased preclinical data on NA-931, originally developed for metabolic disorders such as obesity, the research highlights its potential for treating Alcohol Use Disorder (AUD).
Biomed Industries, Inc. Unveils Groundbreaking research on NA-931 as a Potential Treatment for Alcohol Use Disorder
View press release distributed by EIN Press Access:
https://www.einpresswire.com/article/763705193/biomed-industries-inc-unveils-groundbreaking-research-on-na-931-as-a-potential-treatment-for-alcohol-use-disorder?n=2
Preclinical studies demonstrate that NA-931 significantly attenuates alcohol-induced locomotor stimulation while reducing alcohol intake and alcohol-seeking behaviors in animal models. These results position NA-931 as a promising therapeutic candidate for AUD.
A key advantage of NA-931 is its oral formulation, which offers a more favorable safety profile compared to existing GLP-1-based therapies.
According to the 2023 National Survey on Drug Use and Health (NSDUH), 28.9 million Americans aged 12 and older experienced AUD. Globally, the World Health Organization estimates that AUD affects 400 million people, representing approximately 7% of the population aged 15 and older.
The AUD treatment market reflects the significant growth seen in the obesity drug market. In 2017, the global obesity market was valued at $1.3 billion. Following the introduction of GLP-1-based weight loss therapies, the market is projected to surpass $100 billion in the next five years. Similarly, the AUD drug market, valued at $667 million in 2023, presents immense growth potential as innovative treatments like NA-931 advance.
View a selected list of PUBLICATIONS and PRESENTATIONS at CONFERENCES
For further information about our products, please contact us. Contact us